The Current State of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer

Radical cystectomy with extended pelvic lymph node dissection is the gold standard for the treatment of muscle-invasive bladder cancer (MIBC). Despite this definitive surgery, patients face a recurrence rate of approximately 50% 5 years after surgery. This high recurrence rate may be related to micr...

Full description

Bibliographic Details
Main Author: Oktay Üçer
Format: Article
Language:English
Published: European Medical Journal 2016-04-01
Series:European Medical Journal Urology
Subjects:
Online Access:http://emjreviews.com/wp-content/uploads/The-Current-State-of-Neoadjuvant-Chemotherapy-for-Muscle-Invasive-Bladder-Cancer.pdf
id doaj-4405ec0469aa46dfa7b0c4997ca039e9
record_format Article
spelling doaj-4405ec0469aa46dfa7b0c4997ca039e92020-11-25T01:41:01ZengEuropean Medical JournalEuropean Medical Journal Urology2053-42132016-04-01418893The Current State of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder CancerOktay Üçer0Department of Urology, Faculty of Medicine, Celal Bayar University, Manisa, TurkeyRadical cystectomy with extended pelvic lymph node dissection is the gold standard for the treatment of muscle-invasive bladder cancer (MIBC). Despite this definitive surgery, patients face a recurrence rate of approximately 50% 5 years after surgery. This high recurrence rate may be related to micrometastatic disease at the time of the surgery. Although the data to support adjuvant chemotherapy for treatment of these patients are insufficient, neoadjuvant chemotherapy (NAC) that includes cisplatin-based combination therapy for MIBC is recommended by the guidelines. This article reviews the current situation in NAC for the treatment of MIBC.http://emjreviews.com/wp-content/uploads/The-Current-State-of-Neoadjuvant-Chemotherapy-for-Muscle-Invasive-Bladder-Cancer.pdfBladder Cancermuscle-invasiveNeoadjuvant chemotherapy (NAC)Radical Cystectomy
collection DOAJ
language English
format Article
sources DOAJ
author Oktay Üçer
spellingShingle Oktay Üçer
The Current State of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer
European Medical Journal Urology
Bladder Cancer
muscle-invasive
Neoadjuvant chemotherapy (NAC)
Radical Cystectomy
author_facet Oktay Üçer
author_sort Oktay Üçer
title The Current State of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer
title_short The Current State of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer
title_full The Current State of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer
title_fullStr The Current State of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer
title_full_unstemmed The Current State of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer
title_sort current state of neoadjuvant chemotherapy for muscle-invasive bladder cancer
publisher European Medical Journal
series European Medical Journal Urology
issn 2053-4213
publishDate 2016-04-01
description Radical cystectomy with extended pelvic lymph node dissection is the gold standard for the treatment of muscle-invasive bladder cancer (MIBC). Despite this definitive surgery, patients face a recurrence rate of approximately 50% 5 years after surgery. This high recurrence rate may be related to micrometastatic disease at the time of the surgery. Although the data to support adjuvant chemotherapy for treatment of these patients are insufficient, neoadjuvant chemotherapy (NAC) that includes cisplatin-based combination therapy for MIBC is recommended by the guidelines. This article reviews the current situation in NAC for the treatment of MIBC.
topic Bladder Cancer
muscle-invasive
Neoadjuvant chemotherapy (NAC)
Radical Cystectomy
url http://emjreviews.com/wp-content/uploads/The-Current-State-of-Neoadjuvant-Chemotherapy-for-Muscle-Invasive-Bladder-Cancer.pdf
work_keys_str_mv AT oktayucer thecurrentstateofneoadjuvantchemotherapyformuscleinvasivebladdercancer
AT oktayucer currentstateofneoadjuvantchemotherapyformuscleinvasivebladdercancer
_version_ 1725043000308924416